NASDAQ:LXEO Lexeo Therapeutics Q2 2026 Earnings Report $4.81 -0.18 (-3.61%) As of 11:40 AM Eastern ProfileEarnings HistoryForecast Lexeo Therapeutics EPS ResultsActual EPS-$0.30Consensus EPS -$0.29Beat/MissMissed by -$0.01One Year Ago EPSN/ALexeo Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALexeo Therapeutics Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Lexeo Therapeutics Earnings HeadlinesLexeo Therapeutics Announces SUNRISE-FA 2 Trial Initiation for LX2006 and Receives FDA RMAT Designation for LX2020August 12, 2026 | quiverquant.comQLexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational HighlightsAugust 12, 2026 | globenewswire.comIt’s not about GreenlandThe petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then, China has cut its Treasury holdings by 45% from their peak, and BRICS nations offloaded $47 billion of American debt in a single month. The Trump administration has responded with a $12 billion critical minerals stockpile called Project Vault, equity stakes in miners like MP Materials and Lithium Americas, and a push to secure resources from Greenland to Ukraine. Porter Stansberry lays out the full story in a new documentary, including five companies positioned at the chokepoints of what he calls Trump's New Dollar.August 28 at 1:00 AM | Porter & Company (Ad)Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic CardiomyopathyAugust 5, 2026 | globenewswire.comLexeo’s SUNRISE-FA 2 Trial Puts Gene Therapy for Rare Heart Disease in Investor FocusJuly 22, 2026 | tipranks.comWhat Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could TripleJuly 15, 2026 | finance.yahoo.comSee More Lexeo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lexeo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexeo Therapeutics and other key companies, straight to your email. Email Address About Lexeo TherapeuticsLexeo Therapeutics (NASDAQ:LXEO) is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders. The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments. Lexeo’s lead programs are designed to optimize receptor selectivity and pharmacokinetics, with the goal of delivering rapid onset of action and durable therapeutic benefits in both inpatient and outpatient settings. To advance its clinical development efforts, Lexeo collaborates with academic institutions and contract research organizations across North America and Europe. These partnerships support ongoing Phase 1 and Phase 2 studies, as well as formulation and biomarker development activities that underpin the company’s regulatory strategy. Headquartered in the United States, Lexeo Therapeutics is led by a management team with extensive experience in neuroscience research, drug development and regulatory affairs. The company aims to address significant unmet needs in mental health by translating cutting‐edge science into safe, effective treatments for patients worldwide. View Lexeo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes ShapeCrowdStrike’s “Mythos Moment” Tests the Bigger AI Security TradeIntuit’s Earnings Reset May Be More Pivot Than PlungeOkta Stock Surges 29%—Is $200 the Next Stop?Salesforce Turns the Corner as AI Fears Start to FadeNVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout IsMarvell’s Big AI Test Comes One Day After NVIDIA’s Blowout Quarter Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
